文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

挽救性累及野与扩大野放疗在正电子发射断层扫描阳性淋巴结复发性前列腺癌中的结局与失败模式

Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.
PubMed 文献 · Adv Radiat Oncol · 2022-07-28

本研究回顾性比较了挽救性累及野放疗(s-IFRT)与挽救性扩大野放疗(s-EFRT)在正电子发射断层扫描阳性的淋巴结复发性前列腺癌患者中的结局。2009至2019年间86例患者接受治疗,s-IFRT组38例、s-EFRT组48例。s-EFRT组至姑息性雄激素剥夺治疗(ADT)的时间长于s-IFRT组,两组局部控制均良好。

要点

  • s-EFRT组至姑息性ADT的中位时间未达到,s-IFRT组为24.8个月(P=0.010)。
  • 3年生化失败无失败率s-IFRT组70.2% vs s-EFRT组73.9%(P=0.657)。
  • 3年无远处转移生存率s-IFRT组74.1% vs s-EFRT组82.0%(P=0.338)。

核心结论

  • 对于正电子发射断层扫描阳性的淋巴结复发性前列腺癌,s-EFRT与s-IFRT均提供良好的局部控制。
  • s-EFRT后的至姑息性ADT时间长于s-IFRT后。

研究设计与样本

  • 回顾性研究,纳入2009至2019年间接受s-IFRT或s-EFRT的86例正电子发射断层扫描/计算机断层扫描阳性的淋巴结复发性前列腺癌患者。
  • s-IFRT组38例,s-EFRT组48例。
  • 分析指标包括至生化失败时间、至姑息性ADT时间及无远处转移生存。

主要发现

  • 中位随访41.9个月(范围5.4-122.1个月)后,47例患者出现进一步复发:s-IFRT组31例,s-EFRT组16例,仅1例为野内复发。
  • 至姑息性ADT的中位时间:s-IFRT组24.8个月(95%CI 13.3-93.5个月)vs s-EFRT组未达到(95%CI 40.3个月至未达到),P=0.010。
  • 3年生化失败无失败率:s-IFRT组70.2%(95%CI 51.5%-82.9%)vs s-EFRT组73.9%(95%CI 55.4%-85.7%),P=0.657。
  • 3年无远处转移生存率:s-IFRT组74.1%(95%CI 56.0%-85.7%)vs s-EFRT组82.0%(95%CI 63.0%-91.8%),P=0.338。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal salvage pelvic treatment for nodal recurrences in prostate cancer is not yet clearly defined. We aimed to compare outcomes of salvage involved-field radiation therapy (s-IFRT) and salvage extended-field radiation therapy (s-EFRT) for positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and to analyze patterns of progressions after salvage nodal radiation therapy. METHODS AND MATERIALS: Patients with 18F-fluorocholine or 68Ga prostate-specific membrane antigen ligand positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and treated with s-IFRT or s-EFRT were retrospectively selected. Time to biochemical failure, time to palliative androgen deprivation therapy (ADT), and distant metastasis-free survival were analyzed. RESULTS: Between 2009 and 2019, 86 patients were treated with salvage nodal radiation therapy: 38 with s-IFRT and 48 with s-EFRT. After a median follow-up of 41.9 months (5.4-122.1 months), 47 patients presented a further relapse: 31 after s-IFRT and 16 after s-EFRT, with only 1 in-field relapse. The median time to palliative ADT was 24.8 months (95% confidence interval [CI], 13.3-93.5 months) in the s-IFRT group and not yet reached (95% CI, 40.3 months to not yet reached) in the s-EFRT group (P = .010). The 3-year biochemical failure-free rate was 70.2% (95% CI, 51.5%-82.9%) with s-IFRT and 73.9% (95% CI, 55.4%-85.7%) with s-EFRT (P = .657). The 3-year distant metastasis-free survival was 74.1% (95% CI, 56.0%-85.7%) with s-IFRT and 82.0% (95% CI, 63.0%-91.8%) with s-EFRT (P = .338). CONCLUSIONS: s-EFRT and s-IFRT for positron emission tomography-positive nodal-recurrent prostate cancer provide excellent local control. Time to palliative ADT was longer following s-EFRT than following s-IFRT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pêtre A, Quivrin M, Briot N, et al. Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure. Adv Radiat Oncol. 2022. PMID: 36483057. doi:10.1016/j.adro.2022.101040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。